S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:BLUE

bluebird bio (BLUE) Stock Price, News & Analysis

$0.96
-0.03 (-3.02%)
(As of 04/17/2024 ET)
Today's Range
$0.95
$1.03
50-Day Range
$0.94
$1.75
52-Week Range
$0.88
$5.53
Volume
8.69 million shs
Average Volume
8.99 million shs
Market Capitalization
$105.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.87

bluebird bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
509.4% Upside
$5.87 Price Target
Short Interest
Healthy
27.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of bluebird bio in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$4,134 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.78) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

413th out of 913 stocks

Biological Products, Except Diagnostic Industry

55th out of 134 stocks

BLUE stock logo

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

BLUE Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Is Bluebird Bio Stock a Buy?
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Better Buy: Bluebird Bio Vs. Novavax
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
323
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.87
High Stock Price Target
$13.00
Low Stock Price Target
$1.02
Potential Upside/Downside
+509.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-419.64%
Pretax Margin
-419.50%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
$2.37 per share

Miscellaneous

Free Float
107,040,000
Market Cap
$105.33 million
Optionable
Optionable
Beta
0.74
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Andrew ObenshainMr. Andrew Obenshain (Age 50)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Thomas J. Klima (Age 52)
    Chief Commercial Officer & COO
    Comp: $654.97k
  • Mr. Richard A. Colvin M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $696.24k
  • Mr. Christopher Krawtschuk CPA (Age 50)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Joseph D. Vittiglio Esq. (Age 52)
    J.D., Chief Legal & Business Officer and Secretary
  • Jess Rowlands
    Head of Corporate Communications
  • Ms. Andrea Walton
    Chief People Officer
  • Mr. Kasra Kasraian
    Senior Vice President of Technical Development & Operations
  • Mr. Scott Shoemaker
    Senior Vice President of Quality
  • Ms. Sarah Alspach
    Senior Vice President of External Affairs

BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price target for 2024?

12 analysts have issued 1-year price targets for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's stock price to reach $5.87 in the next twelve months. This suggests a possible upside of 509.4% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2024?

bluebird bio's stock was trading at $1.38 at the beginning of the year. Since then, BLUE stock has decreased by 30.2% and is now trading at $0.9633.
View the best growth stocks for 2024 here
.

Are investors shorting bluebird bio?

bluebird bio saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 29,750,000 shares, a drop of 12.6% from the March 15th total of 34,040,000 shares. Based on an average trading volume of 9,070,000 shares, the days-to-cover ratio is currently 3.3 days.
View bluebird bio's Short Interest
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analysts' expectations of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. bluebird bio's quarterly revenue was up 17364.8% on a year-over-year basis. During the same period last year, the business earned ($0.92) EPS.

What ETFs hold bluebird bio's stock?

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON).Horizon Kinetics Medical ETF (MEDX).

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional investors include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners